Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9062594 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2NPC1 | |
| SCHEMBL458819 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2NPC1 | |
| SCHEMBL14606390 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2NPC1 | |
| SCHEMBL14456382 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2NPC1 | |
| SCHEMBL10608274 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2NPC1 | |
| SCHEMBL30537390 | 0.97 | EPHX1 (0.48) | EPHX1HPGDKMT2AEPHX2NPC1 | |
| SCHEMBL329988 | 0.97 | — | — | |
| SCHEMBL2650273 | 0.92 | — | — | |
| SCHEMBL2566815 | 0.86 | KMT2A (0.39) | EPHX1HPGDKMT2AEPHX2NPC1 | |
| SCHEMBL14947978 | 0.86 | TDP1 (0.35) | EPHX1HPGDKMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228882-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2024129963-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023196458-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196458-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-2362765-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2569281-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | Affectis Pharmaceuticals AG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100168217-A1 | SULFAMATOBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
| EP-1860942-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2006102610-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-4691019-A | Anorectic agent; 4-(3-trifluoromethylphenyl)-1-(2-cyanoethyl)-1,2,3,6-tetrahydropyridine | SANOFI (FR) | 1987-09-01 | — | — | US | disclosed |
| US-4602024-A | Substituted trifluoromethylphenyltetrahydropyridines having a cyano substituent and an anorectic activity, a process for preparing same and pharmaceutical compositions | SANOFI (FR) | 1986-07-22 | — | — | US | disclosed |
| US-4472408-A | Substituted trifluoromethylphenyltetrahydropyridines having an anorectic activity | SANOFI (FR) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168217-A1 | SULFAMATOBENZOTHIOPHENE DERIVATIVES | SULT1A1, SULT1E1, SULT2A1 | EPHX1 678/4885HPGD 909/4885KMT2A 1202/4885 |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | PARK7, UACA, PTGER4 | EPHX1 1197/4885HPGD 198/4885KMT2A 3134/4885 |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | EPHX1 337/4885HPGD 368/4885KMT2A 4614/4885 |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | P2RX7, P2RX3, P2RX2 | EPHX1 788/4885HPGD 1285/4885KMT2A 3068/4885 |
| US-20250228882-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | EPHX1 949/4885HPGD 820/4885KMT2A 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.